Omeros Corporation
OMERHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Omeros Corporation focuses on Biotechnology services and products. Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company carries a $1.37B market cap, placing it firmly in the small-cap category. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome.
Market Cap
$1.37B
Beta
2.60
P/E (TTM)
11.48
P/E (Fwd)
16.55
EPS (TTM)
$1.65
EPS (Fwd)
$1.15
ROE
—
ROA
-18.7%
Cash
$132.0M
Total Debt
$296.9M
Free CF
$183.3M
52W Change
344.8%
Annual Financials
Cash vs Debt
Where OMER stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, OMER finished 54.34% above its 150-day moving average ($12.22) and 56.77% above its 200-day moving average ($12.03). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is OMER overbought or oversold?
At the September 3, 2026 close, OMER's RSI(14) was 63.2, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Omeros Corporation carries $296.9M in total debt against $132.0M in cash reserves — debt is roughly 2.2x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $183.3M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health.
A beta of 2.60 means OMER is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing OMER.